Evidence is emerging that PARP inhibitors could be therapeutics of choice in RCCs that may not carry mutations in the classical BRCA genes, but which have other defects in DNA repair, with recent clinical trials assessing the use of PARP inhibitors in RCC [72, 73]. Here, PARP1 is linked to renal cell carcinoma.